Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives

Table 1 Effect of bevacizumab in phase III Studies in patients with metastatic colorectal cancer

Study	Treatment	Phase	Regimen	Patients (n)	Overall response	Median PFS	Median OS
						(mo)	(mo)
Hurwitz et al[5],	First-line	3	IFL + Bev	402	45%	10.6	20.3
AVF2107 trial,			vs
2004			Placebo	411	35%	6.2	15.5
					P = 0.004	P < 0.001	P < 0.001
Fuchs et al[6],	First-line	3	FOLFIRI (period 1)	144	47%	7.6	23.1
BICC-C trial,			FOLFIRI + Bev (period 2)	57	54.4%	11.2	28.0
2007
Saltz et al[10],	First-line	3	FOLFOX-4 or XELOX + Placebo	701	38%	8.0	19.9
N016966 trial,			vs
2008			FOLFOX-4 or XELOX + Bev	699	38%	9.4	21.3
						P = 0.0023	P = 0.077
Hochster et al[9],	First-line	3	mFOLFOX-6	69	41%	8.7	19.2
TREE1/2 study,			XELOX	48	27%	5.9	17.2
2008			mFOLFOX-6 + Bev	71	52%	9.9	26.1
			XELOX + Bev	72	36%	10.3	24.6
Giantonio et al[11],	Second-line	3	FOLFOX + Bev	290	22.7%	7.3	12.9
ECOG E3200,			Placebo	289	8.6%	4.7	10.8
2007						P < 0.0001	P = 0.0011
Bev beyond progression	Second-line	3	Continued use of Bev + standard	409	5.4%	5.7	11.2
Bennouna et al[12],			2nd-line CTX vs 2nd-line CTX alone	411	3.9%	4.1	9.8
ML18147 (TML),
2012					P = 0.3113	P = 0.0001	P = 0.0062

IFL: Irinotecan/bolus 5-FU/leuvovorin; Bev: Bevacizumab; PFS: Progression free survival; OS: Overall survival; CTX: Chemotherapy.